Janney Montgomery Scott LLC Sells 288,342 Shares of Kenvue Inc. (NYSE:KVUE)

Janney Montgomery Scott LLC lowered its stake in Kenvue Inc. (NYSE:KVUE) by 15.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,538,206 shares of the company’s stock after selling 288,342 shares during the period. Janney Montgomery Scott LLC owned approximately 0.08% of Kenvue worth $32,841,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of KVUE. FMR LLC increased its stake in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares during the period. State Street Corp boosted its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC increased its position in Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after buying an additional 399,846 shares during the period. Finally, Harris Associates L P lifted its holdings in shares of Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after buying an additional 2,186,114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Kenvue stock opened at $20.75 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $39.77 billion, a PE ratio of 37.72, a P/E/G ratio of 2.00 and a beta of 1.46. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s 50-day moving average price is $22.26 and its two-hundred day moving average price is $21.74.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the previous year, the firm posted $0.31 EPS. The firm’s revenue was down .4% on a year-over-year basis. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on KVUE shares. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.